Oswaldo Cruz Foundation

IDRI supports first phase I human hookworm vaccine trial

Wednesday, February 1, 2012

The Infectious Disease Research Institute (IDRI) has joined Sabin Vaccine Institute‘s venture to develop a human hookworm vaccine—which affects 600 million people worldwide—by contributing a proprietary adjuvant as a component. The phase I trial, which began last week in Brazil, aims to reduce the global burden of human hookworm by providing effective long-term protection for those who are most at risk.

[Read More]